Brief: Caladrius Biosciences Says Cend Therapeutics Treated First Patient In Phase 2B Trial Of Cend-1
09/06/2022 13:04
June 9 (Reuters) - Caladrius Biosciences Inc CLBS.O :
* CALADRIUS BIOSCIENCES ANNOUNCES MERGER PARTNER, CEND
THERAPEUTICS, HAS TREATED FIRST PATIENT IN PHASE 2B TRIAL OF
CEND-1 IN COLLABORATION WITH AUSTRALASIAN GASTRO-INTESTINAL
CANCER TRIALS GROUP
Source text for Eikon: ID:nGNX8bFVQj
Further company coverage: CLBS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal